Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
BioSpace reports Vera Therapeutics' newly approved IgA nephropathy drug supports kidney function like Otsuka's Voyxact.
Vera Therapeutics
Vera Therapeutics is a late-stage clinical biopharmaceutical company developing treatments for serious immunological diseases. Its lead asset atacicept (a dual BAFF/APRIL inhibitor) received FDA approval in 2026 for IgA nephropathy (IgAN), establishing it as the first-in-class targeted therapy for this kidney disease.
Company Info
Sector:Biotechnology / Immunology
Headquarters:Brisbane, California, USA
Founded:2016
Website:www.veratx.com/
Recent News
Vera Therapeutics' First-in-Class Kidney Disease Drug Lands Speedy FDA Approval
Vera Therapeutics' First-in-Class Kidney Disease Drug Lands Speedy FDA Approval (MedCity News.)